A Study to Evaluate the Long-term Clinical Safety and Efficacy of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema

Inclusion Criteria

• •Males or females aged 6 years or older.
• •A confirmed diagnosis of HAE type I or II.
• •HAE attacks over a consecutive 2-month period that required acute treatment, medical attention, or caused significant functional impairment.
• •For subjects who have used oral therapy for prophylaxis against HAE attacks within 3 months of first study visit: use of a stable regimen within 3 months of the first study visit.